



Novartis, Novo Nordisk, Pfizer, Roche, and others, to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. The quality and speed of Adimab's platform have been further validated by the use of several Adimab-discovered antibodies in human clinical testing less than three years after Adimab launched its platform. For more information, visit [www.adimab.com](http://www.adimab.com).

Contact:  
Chris Erdman  
MacDougall Biomedical Communications  
(781) 235-3060